Bulletin
Investor Alert

Market Pulse Archives

Aug. 19, 2022, 7:14 p.m. EDT

Novavax COVID-19 vaccine authorized for U.S. teens

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Novavax Inc. (NVAX)
  • X
    Moderna Inc. (MRNA)
  • X
    BioNTech SE ADR (BNTX)

or Cancel Already have a watchlist? Log In

By Jeremy C. Owens

The Food and Drug Administration authorized Novavax Inc.'s /zigman2/quotes/202614340/composite NVAX -1.99% COVID-19 vaccine for use in U.S. teenagers on Friday. Novavax's recombinant protein-based vaccine uses different technology than the mRNA shots developed by Moderna Inc. /zigman2/quotes/205619834/composite MRNA +0.15% and BioNTech SE /zigman2/quotes/214419716/composite BNTX +0.96% , and received an emergency-use authorization by the FDA for adults in July. The vaccine still requires a policy recommendation for use by the Centers for Disease Control, which followed the FDA by about a week when authorizing the Novavax shot for adults. Novavax shares ticked 0.6% higher in late trading Friday, after the announcement; the stock has declined nearly 75% so far this year, as the S&P 500 index /zigman2/quotes/210599714/realtime SPX -1.51% has dropped 11.8%.

/zigman2/quotes/202614340/composite
US : U.S.: Nasdaq
$ 18.20
-0.37 -1.99%
Volume: 3.76M
Sept. 30, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$1.45 billion
Rev. per Employee
$837,729
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 118.25
+0.18 +0.15%
Volume: 3.86M
Sept. 30, 2022 4:00p
P/E Ratio
3.60
Dividend Yield
N/A
Market Cap
$46.19 billion
Rev. per Employee
$8.47M
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 134.88
+1.28 +0.96%
Volume: 735,183
Sept. 30, 2022 4:00p
P/E Ratio
2.58
Dividend Yield
0.00%
Market Cap
$32.42 billion
Rev. per Employee
$7.80M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,585.62
-54.85 -1.51%
Volume: 2.22B
Sept. 30, 2022 5:55p
loading...

Get news alerts on Novavax Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.